A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia.
- 2019-01-22
- RCT · n = 98
- BMC complementary and alternative medicine 19(1)
- Haridas Upadya
- S Prabhu
- Aravinda Prasad
- Deepa Subramanian
- Swati Gupta
- Ajay Goel
- PubMed: 30670010
- DOI: 10.1186/s12906-019-2430-y
- High evidence
- Clinical
Although there was a general trend of FBS reduction, the numbers of participants who may be classified as pre-diabetes and diabetes groups (FBS > 100 mg/dl) in the amla group were only 8.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 500 mg twice daily